Poly (ADP-Ribose) Polymerase-1

A poly(ADP-ribose) polymerase that contains two ZINC FINGERS in its N-terminal DNA-binding region. It modifies NUCLEAR PROTEINS involved in chromatin architecture and BASE EXCISION REPAIR with POLY ADENOSINE DIPHOSPHATE RIBOSE.

Also Known As:

Networked: 505 relevant articles (16 outcomes, 50 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Swanson, Raymond A: 9 articles (11/2016 - 07/2002)
2.	Chiarugi, Alberto: 7 articles (02/2012 - 11/2002)
3.	Wei, Wei: 6 articles (12/2021 - 05/2018)
4.	Virág, László: 6 articles (01/2020 - 02/2002)
5.	Graziani, Grazia: 6 articles (03/2014 - 03/2002)
6.	Tentori, Lucio: 6 articles (03/2014 - 03/2002)
7.	Masutani, Mitsuko: 6 articles (08/2013 - 02/2005)
8.	Lin, Po-Hsiung: 6 articles (01/2013 - 02/2005)
9.	Liu, Songqin: 5 articles (12/2021 - 01/2019)
10.	Strosznajder, Robert P: 5 articles (02/2018 - 01/2005)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2021 - "Numerous studies have established the involvement of Poly (ADP-ribose) Polymerase-1 (PARP-1) in cancer presenting it as an important therapeutic target over recent years. " 01/01/2020 - "Inhibitors of poly (ADP-ribose) polymerase-1 (PARP-1) have shown to be promising in clinical trials against cancer, and many researchers are interested in the development of new PARP-1 inhibitors. " 01/01/2014 - "Inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1) have shown to be promising in clinical trials against cancer and other diseases, and lots of efforts have been put into the development of organic compounds as more potent PARP-1 inhibitors. " 11/30/2023 - "Bioinformatics analyses of Gene Expression Profiling Interactive Analysis (GEPIA), Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE) datasets were applied to explore the relationship between YB-1/PARP1 protein levels and CDK4/6i IC50. " 06/27/2023 - "The inhibition of the DNA damage response pathway, including poly (ADP-ribose) polymerase-1 (PARP-1), has been approved to treat several cancers. "
2.	Inflammation (Inflammations) 05/01/2009 - "It has been suggested that inhibition of poly (ADP-ribose) polymerase-1 (PARP-1), either pharmacologically or by a gene knockout provides significant protection against systemic or tissue inflammation in animal models. " 01/01/2023 - "Moreover, in PH, increased inflammation and oxidative/nitrosative stress cause DNA damage, activating poly (ADP-ribose) polymerase-1 (PARP-1). " 01/01/2021 - "The activity of poly(ADP-ribose) polymerase-1 (PARP-1) is deeply involved in the pathomechanism of inflammation since it leads to energy depletion and mitochondrial failure in cells. " 12/01/2018 - "Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors have been shown to prevent tissue damage in various animal models of inflammation. " 12/01/2013 - "Poly(ADP-ribose) polymerase-1 (PARP-1) is required for both AIF release from mitochondria and NF-κB-mediated inflammation. "
3.	Colitis 02/01/2021 - "Poly(ADP-ribose) polymerase-1 inhibitor ameliorates dextran sulfate sodium-induced colitis in mice by regulating the balance of Th17/Treg cells and inhibiting the NF-κB signaling pathway." 01/01/2009 - "Recent studies in a variety of rodent models of experimental colitis by using PJ-34, a potent poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, support the concept that the marked beneficial effect of PJ-34 can be exploited to treat human inflammatory diseases. " 12/01/2004 - "Activator protein-1 signalling pathway and apoptosis are modulated by poly(ADP-ribose) polymerase-1 in experimental colitis." 01/01/2023 - "While we found no decrease in the levels of NAD+-synthesizing enzymes within the intestinal epithelium of mice undergoing experimental colitis, we did find an increase in the mRNA level, as well as the enzymatic activity, of the NAD+-consuming enzyme poly(ADP-ribose) polymerase-1 (PARP1). "
4.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 07/01/2011 - "Pharmacological inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1) are currently evaluated in clinical trials for various malignancies but, interestingly, also proved of remarkable efficacy in preclinical models of autoimmune disorders including experimental autoimmune encephalomyelitis (EAE). "
5.	Prostatic Neoplasms (Prostate Cancer) 04/15/2013 - "We evaluated the expression of PARP-1 protein in prostatic cancer and normal prostate tissues by immunohistochemistry in 40 men with prostate cancer and in 37 normal men. " 10/15/2010 - "Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation." 11/01/2018 - "Poly (ADP-ribose) polymerase-1 (PARP-1) plays many roles in prostate cancer (PC), such as mediating DNA damage repair, transcriptional regulation and nuclear hormone receptor signaling. " 12/25/2016 - "DIMN-26 also induced apoptosis in LNCap-LN3 and DU145 prostate cancer cells through activation of caspase-3, -8, and -9, and cleavage of poly(ADP-ribose) polymerase-1 (PARP-1). " 04/28/2006 - "In prostate cancer cells the interaction of C/EBPalpha with Ku70, Ku80, and poly(ADP-ribose) polymerase-1 increases sensitivity to DNA damage."

Related Drugs and Biologics

1.	Enzymes
2.	olaparib
3.	Caspase 3 (Caspase-3)
4.	Reactive Oxygen Species (Oxygen Radicals)
5.	Biomarkers (Surrogate Marker)
6.	Poly(ADP-ribose) Polymerase Inhibitors
7.	Transcription Factors (Transcription Factor)
8.	veliparib
9.	Transketolase
10.	Thiamine (Aneurin)

Related Therapies and Procedures

1.	Castration
2.	Induced Heart Arrest (Cardioplegia)
3.	Therapeutics
4.	Drug Therapy (Chemotherapy)
5.	Aftercare (After-Treatment)